PARIS, France, December 22, 2021 at 7:30 p.m. (CET) – Pharnext SA (FR0011191287 – ALPHA) (The “Company”), an advanced clinical biopharmaceutical company pioneering a new approach to the development of innovative drug combinations based on on genomic Big Data and artificial intelligence using its PLEOTHERAPY ™ platform, today announced the establishment of an agreement with its financial partner Global Tech Opportunities 13 (the “Investor”) to amend certain terms of the contract of existing convertible bond financing announced in June 2021 (“the Initial Issue Agreement”). In other words, this amendment provides for reducing to the end of May 2022 the period of issuance of convertible bonds, provides for a waiver of claiming conditions precedent to the drawing of tranches of convertible bonds, thus increasing the degree of certainty in the granting of the financing over the period until May 2022 (the “Amended Issue Agreement”). The Investor has also agreed to reduce the number of Investor Call tranches from seven to one under the new agreement. The maximum gross nominal amount over the period from January to May 2022 will be 15 million euros.